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ABSTRACT OF DISSERTATION 
Effects of solubility, partition coefficient, pH and 
selected adjuvants (propylene glycol and Azone) on the 
percutaneous penetration of isoproterenol HCl in vitro have 
been investigated using human cadaver skin. ·Preliminary 
stability studies demonstrated that isoproterenol HCl was 
very stable ( < l% decomposition) for 24 hours at 220 + o.so 
in the pH range l to 7 in the following solvents: water, 
normal saline, propylene glycol and a series of propylene 
glycol-water mixtures ( 10,20,40 and 60% v/v). The rate of 
decomposition of the drug in aqueous solutions increased 
with pH beyond pH 8. In normal saline, the decomposition 
was significant when the temperature was raised to 370 + 
O.so. The solubility of isoproterenol HCl decreased and its 
skin/vehicle partition coefficient increased with increasing 
proportions of propylene glycol in the vehicle. 
Results of the physicochemical and percutaneous 
penetration studies revealed that 20% vjv propylene glycol 
in water should be the optimal vehicle for transdermal 
delivery of isoproterenol HCl. Optimal penetration 
enhancing effects of AzoneR were seen when incorporated at a 
concentration of l% v/v in the 20% v/v propylene glycol-
water vehicle and more dramatically when the skin was 
pretreated with pure Azone for 60 minutes prior to 
application of the drug formulation. The flux reached a 
maximum around pH 9 in agreement with the predicted 
i 
favorable pH environment for neutral forms of isoproterenol 
HCl. Both neutral and charged forms of isoproterenol HCl 
were found to contribute to the total flux in agreement with 
the proposed model: J = ( Kp . C )Ca + ( Kp . c )an+ ( Kp . 
C )D. The calculated permeability coefficients for 
isoproterenol HCl were 0.2098 x lo-3, 0.1570 x lo-4 and 
-0.8665 x lo-3 cm/h for neutral, cationic and anionic 
species, respectively. Azone enhanced the penetration of 
all forms of isoproterenol HCl, although the effect was more 
pronounced on the anionic species. This may be due to 
facilitation of penetration by formation of an ion-pair 
between isoproterenol HCl and Azone. The permeability 
coefficients for the neutral, cationic and anionic forms of 
isoproterenol HCl for penetration through Azone-pretreated 
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INTRODUCTION 
Transdermal drug delivery systems (l) for systemic 
medication are one of the most promising recent 
innovations developed by the pharmaceutical industry. 
-
Research on transdermal drug administration for the 
systemic delivery of drugs has become very popular 
because it offers the potential for: 
1. reducing frequency of dosing for drugs with 
short biological half lives, 
2. increasing patient compliance, 
3. reducing first-pass metabolism, 
4. avoiding the influence of passage through 
gastrointestinal tract, and 
5. controlling onset and termination of therapy. 
The feasibility of this route of drug administration 
has been successfully demonstrated by introduction of 
products such as Transderm-ScopR, a transdermal 
scopolamine product (2,3), Catapress TTsR, a transdermal 
clonidine product (4-6) and various transdermal 
nitroglycerin products (7), Nitro-DurR, Transderm NitroR, 
NitrodiscR and DeponitR (8-11). 
The designing of an effective transdermal delivery 
.I 
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system is a real challenge for a pharmaceutical scientist 
because of the excellent barrier properties of the skin 
(12,13). Although the skin is one of the largest organs 
in the body and the most readily accessible for 
application of drugs, its surface is one of the least 
permeable as it functions to protect the body from the 
external environment. The skin is essentially composed 
of three main parts, epidermis, dermis and subcutaneous 
tissue. The principle barrier to drug penetration has 
been shown to be the epidermis. Of the various layers of 
epidermis, the stratum corneum, which is the outermosc: 
layer, offers the greatest resistance to drug penetration 
(14). It is a thin, ultradense polyphasic epidermal 
layer made from dehydrated highly filamented dead cells 
which are fused into a tight columnar arrangement. This 
layer has regions rich in protein separated by lipoidal 
framework. In its normal state, the stratum corneum 
contains 15% water. Beneath the stratum corneum, the 
living epidermis is much more hydrophilic in nature. The 
diffusional properties of this region can be considered 
to be similar to those of an aqueous protein gel (12). 
Beneath this lies the dermis, a region highly perfused by 
blood and lymph vessels. This microcirculation network 
provides an efficient means of drug removal into the 
systemic circulation. The composition of the various 
3 
layers of skin largely explains its varying degrees of 
penetrability. Each penetrant may encounter a different 
type of barrier depending upon its chemical and physical 
properties and potential interaction with the tissues. 
Early investigations have shown that drugs to be 
formulated into transdermal products must be stable, 
preferably have a molecular weight of less than 1000 and 
melting point of less than 2000 F, possess solubility in 
both hydrophilic and lipophilic solvents and have pH of 
5-9 in saturated aqueous systems (13). These properties 
affect the most essential characteristic of the drug, 
namely, its permeation across the skin in therapeutically 
potent amounts over an acceptable area. Another 
requirement for acceptability is the drug's freedom from 
localized irritating or allergenic effects. In practice, 
very few drugs could meet all of these criteria and a 
variety of approaches must be tried in order to 
successfully formulate poorly penetrating drugs into 
transdermal delivery systems. 
Early attempts to improve percutaneo.us penetration 
of weakly penetrating drugs focused primarily upon 
suitably altering penetrant solubility (15) and 
skin-vehicle partitioning (16) by judiciously blending 
two or more solvents (17,18). Poulsen et al. (19) and 
Ostrenga et al. (20) successfully demonstrated the 
4 
application of this approach to the formulation of a 
dermatologic preparation for fluocinolone acetonide and 
its 21-acetate ester. Studies conducted by Coldman et 
al. (21) have shown that percutaneous penetration of 
corticosteroids could be improved by incorporating a 
volatile component in the vehicle. Recently Nagai et al. 
(22) reported that a gel ointment of 55% ethyl alcohol/ 
propylene glycol containing propranolol gave distinctly 
higher plasma levels as compared to conventional 
propranolol ointments when administered topically. 
Sarpotdar et al. (23) showed that polyethylene glycol 400 
has a significant barrier specific effect on the 
penetration rates of compounds and that these effects 
were related to the alteration of skin structure and the 
mass flow of water. The effect of particle size and 
vehicle on the percutaneous penetration of fluocinolone 
acetonide was earlier investigated by Barrett et al. 
(24). They found that particle size plays an important 
role in percutaneous penetration of fluocinolone 
acetonide and that the incorpc:·ation of propylene glycol 
into the vehicle enhanced the percutaneous penetration of 
this steroid. Various other studies (25-27) have shown 
that the incorporation of propylene glycol into the 
vehicle increased percutaneous penetration of various 
compounds. These studies also revealed that propylene 
5 
glycol penetrates the skin rather easily and that the 
skin resistance to propylene glycol decreased as the 
weight fraction of propylene glycol was increased. 
Together the aforementioned studies strongly suggest that 
propylene glycol increases percutaneous penetration of 
drugs by reducing the diffusional resistance of the skin 
barrier and increasing the thermodynamic flux of the drug 
by increasing its solubility in the vehicle. 
Various investigations (28-31) have documented the 
effect of pH in the absorption of ionizable drugs through 
the gastrointestinal tract. The unionized drug molecules 
have a better penetration rate compared to ionized 
molecules due to the lipophilic nature of the 
gastrointestinal membrane. Similar observations have 
been made in early percutaneous penetration studies 
(32,33) conducted with ionizable drugs. Adriani and 
Dalili (34) found that salts of local anesthetic agents 
have very poor penetrability through the skin. Arita et 
al. ( 33), in their investigation with sal icy lie acid as 
an acidic drug and carbinoxamine as basic drug, showed 
preferential penetration of the unionized form over 
ionized form. Swarbrick et al. (35) in their studies 
with ionizable compounds showed the influence of pH on 
percutaneous penetration of four related 4-oxo-4-H-1-
benzopyran-2-carboxylic acids. It was reported that 
__ :
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chromone-2-carboxylic acids permeate the human skin both 
as unionized and ionized species, although the former are 
approximately 104 times more permeable. Recently, 
Vaidyanathan et al. (36) have studied the effect of pH 
and solubility on the skin penetration of methotrexate 
from a 50% (v/v) propylene glycol-water vehicle. A pH of 
4 to 5 was shown to be the most favorable environment for 
percutaneous penetration of methotrexate since the 
concentration of the unionized species at that pH is 
optimal. 
Another popular approach to improve percutaneous 
penetration of drugs focuses primarily upon the use of 
adjuvants to diminish the skin's resistance to 
penetration of drug molecules. The effect on the skin 
should be mild and/or reversible. A variety of compounds 
(37) including many surfactants (38-42), dimethyl 
sulfoxide (43), 2-pyrrolidone (44-50), N-methyl-2-
pyrrolidone (46-49) and AzoneR (1-dodecylazacycloheptan-
2-one) (Figure 1) have been extensively studied. Among 
these, 2-pyrrolidone has been the subject of the most 
recent reports. Although Chow (51) recently reported 
that Azone affects the cell proliferation of cultured 
human and mouse L-929 skin fibroblasts, Azone appears to 
have considerable potential because of its documented 
l __ _ .I -
=0 
N- [CH2 111 Cll3 
. 1 - Dodecyluzncycloheptnn - 2- one 
c1 aH3sNO F.W. = 281.49 
R 
Figure 1. Chemical structure of Azone . 
__, 
lack of irritation and side effects. Azone at 
concentrations of 1-10%, has been shown to enhance 
penetration of most of the drugs studied by a factor 
which may be as much as hundreds of times the control 
values (52,53). Several studies have attempted to 
evaluate the effect of Azone on the percutaneous 
8 
penetration of triamcinolone acetonide (54,55), methanol 
(56), 8-bromoadenosine 3', 5'- hydrogenphosphate, 
9-B-D-arabinofuranosyladenine (57), arabinofuranosyl-
adenine 5'-valerate (58), 5-fluorouracil (59,60), 
indomethacin and hydroquinone (59), hydrocortisone (50), 
mannitol (50), hexyl nicotinate (61), 6-carboxy-
fluorescein (62), trifluorothymidine (63) and 
metronidazole (64). These studies have shown that Azone 
indeed enhances the percutaneous penetration of these 
drugs. Stoughton (54) reported that percutaneous 
penetration of triamcinolone acetonide through human skin 
in the presence of 10% Azone was 5-10 fold higher. 
Similar results were obtained by Chow et al. (55), when 
they investigated the percutaneous penetration of 
triamcinolone acetonide through hairless mouse skin. 
Greater enhancement was observed with 5-fluorouracil and 
indomethacin at Azone concentrations of 1.8-45% (59). In 
another study by Sugibayashi et al. (60), similar results -- --
were observed with 5-fluorouracil. Bennett and Berry 
9 
(50) showed that Azone in presence of propylene glycol 
enhanced the percutaneous penetration of polar and non-
polar compounds. Behl et al. (56) demonstrated that the 
permeability of methanol was promoted 200-400 fold by 
Azone with maximal enhancement at 10-25%. Vaidyanathan 
et al. (57) showed an 170-fold increase in the 
penetration of 9-B-D-arabinofuranosyladenine over the 
control values. Enhanced skin penetration of hexyl 
nicotinate in presence of Azone in human subjects using 
laser Doppler velocimetry was demonstrated in a recent 
study by Ryatt et al. (61). Wotton et a 1. ( 6 4) observed 
prolonged enhancement of percutaneous penetration of 
metronidazole lasting over several days following single 
application of Azone. Ohshima et al. (62) have shown 
that Azone promotes the penetration of a poorly 
penetrating dye, 6-carboxyfl uorescein. Sheth et al. ( 6 3) 
recently reported that Azone and propylene glycol enhance 
membrane permeability of trifluorothymidine and act 
synergistically when formulated together. Recently, 
BenKorah (65) has confirmed earlier findings of Lam (66) 
that Azone increases the skin penetration flux of 
benzocaine from selected propylene glycol/water vehicles 
by directly affecting the skin's barrier characteristic's. 
It appears that for lipophilic drugs, such as benzocaine, 
drug solubility in Azone might adversely effect the 
10 
skin/vehicle partitioning of the drug. This would make 
selection of the proper Azone concentration level in the 
vehicle is of critical importance. Literature has very 
few citations regarding effect of Azone on percutaneous 
penetration of ionizable compounds. Recently, Hadgraft 
et al. (67) reported that Azone facilitates the transport 
of salicylate ion across an isopropyl myristate membrane 
by forming ion pairs. This would suggest that the 
selection of proper Azone concentration in the vehicle is 
also of critical importance for hydrophilic drugs as 
Azone will adversely affect the partitioning of the drug 
into the skin. 
! 
From the published reports, it would appear that 
' I 
I. Azone enhances the percutaneous pene·tration of drugs 
without detectable toxicity, altering sensitivity or 
inducing other systemic or local side effects. 
Radioactive studies have shown that Azone is bound in the 
epidermis and corium and that only relatively small 
amounts are released from the skin (68,54). The precise 
mechanism is unknown but the well documented penetration 
enhancing effects of Azone could be due to alteration of 
the lipid-protein structures of the stratum corneum 
and/or due to its role as a carrier of drug molecules 
-j across the skin by formation of ion-pairs. 
Collectively, these and other studies reinforce the 
11 
concept that design of an optimal vehicle for topical 
delivery of a drug is likely to involve carefully 
orchestrated compromises as one attempts to balance often 
opposing influences of vehicle components with respect to 
drug solubility, skin partitioning, and its membrane 
structure altering properties. 
Selection of a Model Membrane for In Vitro Percutaneous 
Penetration Studies 
A variety of models have been investigated over the 
years to study percutaneous penetration of drugs in 
humans. Early work utilizing membraneless systems was 
conducted by Poulsen et al. (69). Ostrenga et al. 
(20,70) studied the release of fluocinolone aceto~ide and 
its acetate from propylene glycol-water gel systems into 
stirred isopropyl myristate acting as a diffusional sink. 
Various living membranes such as frog skin (71), the 
membrane encasing the chick embryo (72-74), man-made 
membranes such as the hydrated dialysis membranes (75), 
porous cellulosic membranes with lipid-filled interstices 
(76), and silicone rubber films (77) have also been 
utilized. Unfortunately, none bears even close 
resemblance to skin and all of these studies were 
questionable on the same grounds as membraneless systems 
12 
for their ability to mimic ln vivo conditions. 
The other alternative to human skin, still popular 
with some researchers, is the use of animal skin. Wester 
and Maibach (78), have documented the work of several 
investigators using animal skin models for percutaneous 
penetration studies. The skins of various animals such 
as rats, rabbits, mice, monkeys, and pigs have been used. 
But, there are documented (79) differences of opinions 
among the researchers regarding the merits of this 
approach. Durrheim et al. (80) and Stoughton (81) 
reported that hairless mouse skin is similar to human 
skin for some compounds, but Bronaugh et al. (82), have 
shown that this may depend on the nature of the compound 
and is certainly not always the case. Walker et al. (83) 
showed that there was a significant difference in the 
rates of permeation between the hairless mouse and human 
skin for various compounds. Similarly, with the rat, 
Bartek et al. (84) concluded that the permeability of the 
rat skin is not similar to human skin. These apparent 
discrepancies can be explained by the structural 
differences between human and animal skin. Although it 
has been argued (85) that the results of in vitro 
percutaneous penetration studies using human cadaver skin 
cannot be correlated to in vivo percutaneous penetration, 
human cadaver skin seems to be the most nearly ideal 
13 
alternative to human skin in vivo at present. 
Therefore, in this investigation all penetration studies 
were condu,cted using excised human cadaver skin. 
Selection of Isoproterenol HCl as a Model Drug 
Isoproterenol [ 4- (1-hydroxy-2 [ ( 1-methylethyl) 
amino]ethyl)-1,2-benzenediol] (Figure 2) is a direct-
acting sympathomimetic amine which acts on beta-
adrenergic receptors. It is generally used as a 
bronchodilator and cardiac stimulant. It is readily 
absorbed when given parenterally or administered as an 
aerosol. Absorption following oral or sublingual 
administration is erratic and unreliable (86,87) 
Isoproterenol HCl undergoes two types of metabolic 
transformations after oral administration. It is 
converted to a sulfate conjugate in the gut wall and it 
is also metabolized by hepatic catechol'-0-methyl 
transferase to methoxy-isoproterenol (88-90). Following 
an IV dose, 50% appears unchanged in the urine. After an 
oral dose, 8% is excreted unchanged and 90% is excreted 
as the conjugate (91,92). Hence, the oral dose is larger 
than the parenteral dose. The plasma half-life of 
isoproterenol hydrochloride ranges from a few minutes 
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subcutaneous or sublingual administration and 2-4 h after 
rectal administration of a sublingual tablet. 
Isoproterenol HCl is administered intravenously at a 
dose of 20-60 meg initially followed by 10-200 meg as 
needed to elicit the needed response (93) indicating 
significant inter-individual variation. The recommended 
oral or sublingual dose ranges from 10-15 mg gi£, but not 
more than 60 mg in a day. It is also administered by 
inhalations as 1:200.- 1:100 solution~ (94). An 
infusion of 1:500,000 solution is given at a rate of 5 
meg/min (95). 
Isoproterenol HCl is highly metabolized when given 
orally (96). It has a very short biological half-life 
when administered intravenously, orally or sub lingually. 
Furthermore it shows an erratic and unreliable absorption 
following oral or sublingual administration. These 
considerations provided strong incentive for 
investigating transdermal delivery of isoproterenol HCl. 
Transdermal delivery of isoproterenol HCl would eliminate 
first-pass metabolism and the variability in absorption 
associated with gastrointestinal t"ansit. A successful 
transdermal system would also increase patient compliance 
due to a reduction in frequency of dosing associated with 
intravenous and oral routes. 
Preliminary in vitro studies revealed that 
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isoproterenol HCl, a highly water soluble salt, had a 
poor penetration rate through human cadaver skin. This 
was not unexpected in view of its ionic character and in 
light of the numerous studies (discussed earlier) 
documenting that percutaneous penetration of most drugs 
follows Fickian diffusion. In fact, isoproterenol HCl 
offered an excellent opportunity to test the percutaneous 
penetration enhancing effects of Azone on an ionizable 
compound. 
Scope of Present Study 
This study is intended to examine the effect of 
various physicochemical factors such as solubility, 
partition coefficient and pH on in vitro percutaneous 
penetration of isoproterenol HCl from a propylene glycol-
water system across excised full-thickness human cadaver 
skin from the abdominal region. The penetration 
enhancing effect of Azone on .different ionic species of 
isoproterenol will also be examined and evaluated by 
varying the vehicle pH. In addition to helping define 
optimal conditions for transdermal delivery of 
isoproterenol HCl, it is hoped that this investigation 
will contribute to a better understanding of. the 
percutaneous penetration of ionizable drugs and lead to 
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insights into the mechanisms by which Azone enhances the 
percutaneous penetration of ionizable drugs. 
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THEORY 
Percutaneous penetration of most drugs through human 
skin is a passive diffusion process described by Pick's 
first law of diffusion. Equation 1 (97) is the 
mathematical expression frequently used to describe this 
membrane-limited transport under steady-state conditions. 
The amount of drug absorbed through the membrane per unit 
area per unit time, also known as flux, J can be readily 
calculated from equation 1, where, 
D P 
J = ----- c 
h 
(Eq. 1) 
D is the diffusion coefficient of the drug within the 
membrane, h is the membrane thickness and P is the 
membrane/vehicle partition coefficient. The quantity (D 
P/h) is referred to as the permeability constant or 
permeability coefficient, Kp. 
J = Kp . C (Eq. 2) 
The drug concentration, C, in the vehicle must remain 
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constant during the course of the penetratlon experiment 
and the receptor chamber should mimic a perfect sink. In 
investigations using human cadaver skin, the stratum 
corneum generally functions as the rate-limiting barrier. 
Therefore, the parameters D, P, and h in equation l are 
determined with reference to this skin layer. Upon 
closer examination, it is evident that equation l is very 
useful in identifying the factors that could be 
manipulated to control percutaneous penetration rate or 
flux (J). Assuming that the diffusion coefficient D and 
skin thickness h remain constant, the flux would be 
directly related to the product of partition coefficient, 
P and drug concentration in the vehicle, C. Therefore, 
flux can be controlled by varying formulation parameters, 
which alter P and/or C. Both drug partitioning into the 
skin and drug concentration in the vehicle can be altered 
by judicious choice of solvents and other adjuvants for a 
given drug. In practice, one must strike a balance 
between drug solubility in the vehicle and its 
partitioning into the skin in order to attain clinically 
meaningful flux values. To attain this objecti,·e, 
solubility and partition coefficient (98) information of 
drugs have been utilized to develop predictive models for 
optimizing drug availability with limited success . 
It is well documented (32-36) that the passive 
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diffusion process across the skin favors neutral 
molecules or the uncharged form of ionizable molecules 
due to their lipophilicity. Therefore, the pH of the 
vehicle plays an important role in the percutaneous 
penetration of ionizable drugs. The flux of the 
ionizable drugs can be affected by changes in pH due to 
resulting alteration in the ratio of charged to uncharged 
species . 
. Isoproterenol at any given pH exists as an 
equilibrium mixture of cationic, anionic, uncharged and 
zwitterionic species as shown in Figure 3. The 
concentrations of the various species as a function of pH 
an shown in Figure 4. These concentrations were 
calculated on the basis of macro- and micro-dissociation 
constants (pKal = 8.83, pKa2 = 10.19; pKl = 9.58, pK2 = 
8.91, pK3 = 9.44, pK4 = 10.11) at 2soc as published by 
Sinistri and Villa (99,100). The percentages of the 
individual species of isoproterenol HCl present at 
different pH values were calculated by following 
equations (101-103): 
% Cation= 100/( 1 + pK2/(H+) + pKl/(H+) + pKl.pK3/(H+)2) 
( Eq. 3) 
% Uncharged= 100/( 1 + (H+)/pKl + pK3/(H+) + pK2/pKl) 
( Eq. 4) 
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Figure 4. The percent of the different ionic forms of 
isoproterenol HCl as a function of pH. 
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% Zwitterion = 100/( 1 + (H+)/pK2 + pK4/(H+) + pKl/pK2) 
( Eq. 5) 
%Anion= 100/( 1 + (H+) /pK4 + (H+) /pK3 + {H+) 2jpKl.pK3) 
( Eq. 6 ) 
Assuming that all species contribute to the total 
steady-state flux, solely by their own concentration 
gradient and unaltered by the presence of other species, 
equation 1 can be rewritten as, 
( Eq. 7) 
where the total flux, J is a sum of contributions by 
cationic (JCa), anionic (Jan), and uncharged and 
zwitterionic (Jn) species. By appropriate substitution, 
we get equation 8: 
J = ( Kp . c )Ca + ( Kp . c )an + ( Kp . c )n 
( Eq. 8) 
The individual permeability coefficients for 
different species Kpca, Kpan, and Kpn can then be 
statistically determined by means of the method of least 
squares if the flux, J and concentration (cca, can and 
en) are known. J can be determined experimentally for 
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any formulation at a given pH and total drug 
concentration cca, can and en values at any particular pH 
can be calculated using equations 3, 4, 5 and 6. The 
calculated permeability coefficients of various species 
can then be compared to assess the relative 
permeabilities of human cadaver skin to these species of 
isoproterenol HCl. 
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EXPERIMENTAL: PHYSICOCHEMICAL STUDIES 
Isoproterenol HCl is known to be very unstable in 
solution in presence of light, air and in solutions of 
high pH values. In order to define the experimental 
conditions and formulation parameters for studying 
percutaneous penetration of isoproterenol HCl and the 
penetration enhancing effects of Azone, it was necessary 
to generate relevant stability, solubility and 
skin/vehicle partition coefficient data. 
The stability of isoproterenol HCl was determined in 
a series of propylene glycol-water mixtures, normal 
saline and distilled water. The solubility of 
isoproterenol HCl in a series of propylene glycol-water 
mixtures and Azone was also determined. Finally, the 
partitioning of isoproterenol HCl from various propylene 
glycol-water mixtures into human cadaver skin was studied 
to complete this phase of the investigation. 
Assay Methods 
Analysis. of samples for isoproterenol HCl content 
were carried out by ion-pair high-performance liquid 
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chromatography by the method of Ghanekar and Das Gupta 
(104) and also spectrophotometrically (105). 
The chromatograph was equipped with a 6000-psi 
pumpl, a variable wavelength detector2 and a loop 
injector3. A 250-mm long, 4.6-mm diameter stainless 
steel column4 was used. The accurate determination of 
area under the curve was accomplished by use of an 
automated integrator systemS. Injection volume was 
maintained constant with a 20 ul loop installed in the 
loop injector and the injections were made with the aid 
of a 25 microliter gas-tight syringe6. The eluent was a 
20% (v/v) solution of methanol? in water containing 2% 
(v/v) acetic acidS with 0.005 M sodium 1-heptane-
1. · Waters 6000-A pump, Waters Associates, Milford 
MA. 
2. Model 450, Variable Wavelength Detect::>r, Waters 
Associates, Milford MA. 
3. U6K Injector, Waters Associates, Milford MA. 
4. Nucleosil Cl8• All tech Associates Inc., 
Deerfield IL. 
5. Data Module, Waters Associates, Milford MA. 
6. 600 Series syringe, Hamilton Co., Reno NV. 
7. HPLC grade, J. T. Baker Chemical Co., 
Phillipsburg NJ. 
8. HPLC grade, J. T. Baker Chemical Co., 
Phillipsburg NJ. 
sulfonate9. The pH of the eluent was 2.6 + 0.05. 
Epinephrine bitartratelO was used as an internal 
standard. The analysis was conducted at room 
temperature. The flow rate was 2.0 mL/min at inlet 
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pressure of approximately 1800 psig. The absorbance was 
measured at 280 nm and the detector was set at 0.1 aufs 
and sensitivity at 0.02. The chromatogram of a standard 
mixture of isoproterenol HCl (100 mcg/mL) and epinephrine 
bitartrate (100 mcg/mL) is shown in Figure 5. The 
retention time for isoproterenol HCl was 6.25 minutes and 
for epinephrine bitartrate (internal standard) was 3.91 
minutes. A calibration plot constructed using ratio of 
area under the peak of the standard samples to the 
internal standard is shown in Appendix l. 
The spectrophotometric analysis of isoproterenol HCl 
samples was conducted using a Spectronic 710 
spectrophotometerll set at 280 nm. The standard curves 
of-isoproterenol HCl in distilled water and normal saline 
are shown in Appendix 2 and 3, respectively. 
9. Lot 26867X, ICN Biomedicals Inc., K & K 
laboratories, Plainview N.Y. 
10. Lot E-4375, Sigma Chemical Co., St. Louis MO. 








Chromatogram of isoproterenol HCl and 






10 u Nucleosil C1s 
20/80 methanol/water with 
2% v/v acetic acid and 0.005 
M sodium 1-heptane sulfonate, 
pH = 2.6 
2.0 mL/min 
0.5 em/min 
: at 280 nrn.,· set at 0.1 AUFS 
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Stability Studies 
Stability in distilled water: The stability of 
isoproterenol HCl in distilled water was determined in 
solutions ranging from pH 1.93 to 10.1 at 220 + 0.5°. 
Five mL of solutions (100 mg/mL) of isoproterenol HCl 
bufferedl2 to appropriate pH values (1.93-6.53) were 
stored in glass vials for 24 h. After 24 h one mL of the 
solution from each vial was withdrawn by a pipettel3 and 
diluted to 100 mL in a volumetric flask and analyzed by 
HPLC. The percent isoproterenol remaining was calculated 
as a mean of three separate determinations. A more 
detailed study was conducted at pH values 8, 9 and 10 to 
determine the extent of decomposition after 0, 3, 6, 9, 
12 and 24 h periods and the procedure was similar to one 
described above. 
Stability in Propylene glycol-water mixture: The 
stability of isoproterenol Hcll4 was determined in a 
12. pHydrion Buffers, Micro Essential Laboratory 
Inc., Brooklyn NY. 
13. Pipetman (5 mL), West Coast Scientific, Oakland 
CA. 
14. Sigma chemical Co., St. Louis ~10. 
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series of propylene glycollS-water mixtures (10%, 20%, 
40% and 60% v/v) at 220 + o.so over a pH range of 1.93-
7.38. Five mL samples of freshly prepared solutions (100 
mg/mL) of isoproterenol HCl buffered to appropriate pH 
values in various vehicles were stored in 10 mL glass 
vials for 24 h. Then one mL of the solution from each 
vial was withdrawn and pipetted and diluted to 100 mL in 
a volumetric flask and analyzed by HPLC. The percent 
isoproterenol remaining was calculated as mean of three 
separate determinations. 
Stability in normal saline: The stability of 
isoproterenol HCl was determined in normal salinel6 at 
220 + o.so and at 370 + O.so in the absence and presence 
of 0.01% and 0.02% EDTA17 (ethylenediamine tetraacetic 
acid), respectively. Freshly prepared solutions (100 
mcg/mL) of isoproterenol HCl in normal saline was stored 
in glass vials at 370 + O.so in an incubator. At time 
intervals of 1.5, 3, 6, 12 and 24 h samples were taken 
and analyzed for isoproterenol HCl content by HPLC. The 
percent isoproterenol HCl remaining was calculated as a 
15. USP grade, J. T. Baker Chemical Co., 
Phillipsburg NJ. 
16. 0.9% Sodium Chloride Injection, USP, Travenol 
Laboratories Inc., Deerfield IL. 
17. Stock# ED2SS, Sigma Chemical Co., St. Louis MO. 
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mean of three separate determinations. 
Solubility Studies: 
The solubility of isoproterenol HCl in a series of 
propylene glycol-water (0, 10, 20, 40, 60 and 100% v/v) 
mixtures and Azonel8 was determined at 220 + 0.5o. In 
all cases, an excess of isoproterenol HCl was added to 5 
mL of·the solvent in a 50-mL amber colored Erlenmeyer 
flask with a ground glass stopper. A Teflon-coated 
magnetic stirring bar was placed in each of the flasks 
prior to flushing with nitrogen and capping them tightly. 
The solution was then stirred on a magnetic stirrer for 
24 h. All studies were conducted at least in duplicate. 
Preliminary studies at 24 and 48 h revealed that 
equilibration could be attained in 24 h. Prior to 
sampling, the stirring was stopped and the excess drug 
was allowed to settle. An aliquot of the supernatant was 
taken and filtered with 0.22u filter using a syringe with 
millipore adapt.erl9. The first fe•1 mL of the filtrate 
were discarded to avoid any error due to the possible 
saturation and adsorption of the drug to the filter. 
After appropriate dilution, the concentration was 
18. Lot# 059N0803, Nelson Research, Irvine CA. 
19. Swinnex-25, Millipore Filter Corp., Bedford !VlA. 
-! 
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determined by HPLC as discussed under assay method. 
Skin/Vehicle Partitioning Studies 
Preliminary experiments had shown that isoproterenol 
HCl reached equilibrium distribution between the vehicle 
and skin in three days. 
Skin preparations of known weight (100-200 mg) were 
prepared and equilibrated with solutions of isoproterenol 
HCl in selected propylene glycol-water mixtures in 50-mL 
amber colored Erlenmeyer flasks by agitation for 3 days 
at 220 + 0.5o after flushing with nitrogen. Initial and 
equilibrium drug concentrations in the vehicle 1vere 
assayed using HPLC. The skin samples were washed once 
with about 5 mL of distilled water and isoproterenol HCl 
in the skin was determined by homogenizing it with known 
volume of distilled water. The homogenate was filtered 
through 0.22u filter paper with a syringe fitted with 
millipore adapter. The first few drops of the filtrate 
were discarded due to saturation and adsorption of the 
drug to the filter. ·An aliquot of the filtrate was 
appropriately diluted and analyzed by HPLC. 
The skin/vehicle partition coefficient (Ksjv) was 
then calculated from equation ll derived as follows 
(106): 
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Ksjv = = ------------- ( Eq. 9 ) 
where, Cs and Cv are the drug concentrations in the skin 
and in the aqueous solution, respectively, at 
equilibrium; Ms and Mv are the masses of isoproterenol in 
the skin and in the vehicle respectively, at equilibrium; 
Vs and Vv are the volumes of the skin and the vehicle, 
respectively. The Ms may be expressed in terms of Mv and 
Mvo, the total mass of drug initially present in the 
aqueous solution: 
_: 
( Eq. 10) 
Therefore, Eq. 3 may be rearranged to give: 
= 
= ------------------------- (Eq. 11) 
where Cv0 is the initial concentration of drug in the 
vehicle. 
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RESULTS Al~D DISCUSSION: PHYSICOCHEMICAL STUDIES 
Stability Studies 
The stability of isoproterenol HCl in distilled 
water, normal saline, 10%, 20%, 40% and 60% (v/v) 
propylene glycol in water at 22° + O.so is shown in Table 
I. The analysis of data revealed that isoproterenol HCl 
was stable in these vehicles at pH values ranging from 
1.9 to 7.38. Almost 99% of the initial amount of 
isoproterenol HCl present could be accounted for at the 
end of 24 h. The stability of isoproterenol HCl in 
distilled water at pH values 8, 9 and 10.1 was also 
determined in order to study the extent of decomposition 
under high pH conditions. Table II shows that increasing 
the pH of the solution resulted in an increase in the 
rate of decomposition. This information was later 
utilized to select range of pH values for the 
percutaneous penetration studies. 
Since the fluid in the receptor chamber of the 
diffusion cell was normal saline maintained at 370 + 
0.5°, it was necessary to study the stability of 




Stability of Isoproterenol HCl in Water, Normal Saline 
and Propylene Glycol-Water Mixtures 
1 
pll Amount pH Amount pH Amount 




Distilled water 1.9 98.95 3.8 98.78 5.2 98.29 6.5 
± 0.91 ± 4.59 ± 2.43 
Normal Saline 1.9 98.86 3.7 96. 81 5. 3 98.23 6.5 
± l. 30 ± 2.04 ± 2.04 
10% (v/v) PG/DW 2.0 99.24 3.6 98.7 5. 9 98.72 6. 6 
+ 0.83 + 0.80 + l. 46 
20% ( v /V) PG/DI'I 2.0 99.77 3.8 99.67 6.3 99.16 6. 7 
+ 0.52 ± 0.42 + 0.90 
40% {v/v) PG/DW 2.1 99.72 3. 6 98.53 6.3 101.65 7. 2 
+ 0.06 + 0.83 ± 1.09 
60% {v/v) PG/DW 2.2 100.24 3.7 ·98.28 7. 1 99.92 7.4 
+ 0.67 + 2.54 ± 0. 25 
1 0 0 
Values were determined after storage at room temperature { 22 ± 0.5 
for 24 hours and are expressed as a mean of three determinations 


















stability of Isoproterenol HCl in Distilled \'later 




Time, h Amount Left, % 
------------------------------------------------
pH 8.0 pH 9. 0 pH 10.1 
-----------------------------------------------------------
0 100.00 + 0.00 100.00 + 0.00 100.00 + 0.00 
3 99.15 + 0.00 100.32 + 0.01 91.62 + 0.04 
6 97.11 + 0.00 96.60 + 0.01 60.57 + 0.02 
9 96.10 + 0.00 88.26 ±. 0.02 28.29 + 0. 17 
12 98.03 + 0.00 73.31 ± 0.01 36.57 + 0.02 -
24 94.07 + 0. 01 50.81 + 0.02 30.61 + 0.01 
1 0 0 
Values are determined at 22 ± 0.5 and expressed as mean 
of three determinations + standard error of mean. 
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The stability of isoproterenol HCl in normal saline with 
and without 0.01% and 0.02% EDTA was determined at 370 + 
o.so (Table III). The traces of metallic ionic 
impurities in aqueous solutions of isoproterenol HCl are 
reported to accelerate its oxidative decomposition. EDTA 
has been used alone and in conjunction with other 
antioxidants to stabilize the aqueous formulations of 
isoproterenol HCl (107). In the present study, 0.01 and 
0.02 % concentrations of EDTA did not produce marked 
improvement in stability of isoproterenol HCl in normal 
saline. Therefore, EDTA was not used to stabilize 
isoproterenol HCl solutions in this study. The data in 
i _, 
Table III also revealed that decomposition of the drug in 
normal saline was minimal during first 2 h. Therefore 
sampling times in percutaneous penetration studies never 
exceeded 2 h. 
Solubility Studies 
The solubilities of isoproterenol HCl in distilled 
water, propylene glycol, Azone and 10%, 20%, 40% and 60% 
(v/v) propylene glycol in water at 220 + o.so are shown 
in Table IV, Figure 6. 
_j Isoproterenol HCl is highly soluble in water, 




Stability of Isoproterenol HCl in Normal Saline at 37 ± 0.5 
1 
1 








Normal Saline Normal Saline 
+ 0.01% EDTA 
100.00 100.00 
+ 0.00 + 0.11 
100.21 96.38 
+ 0 .14 + 0.58 
88.5 84.59 
+ 0.06 ± 0.05 
88.26 91.08 
.±. 0.11 + 0.18 
81.52 79.67 
+ 0.07 ± 0.07 
50.33 60.1 
+ 0.08 + 0.13 
Normal Saline 













Values are expressed as mean of three determinations 
~ standard error of mean 
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TABLE IV 
Solubility of Isoproterenol HCl in Selected Solvents 
l 2,3 3,4 
Vehicle N pH Solubility, 
mg/ml 
------------------------------------------------------------
Distilled Water 6 3.9 + 0.1 
10% PG/DW 2 3.9 + 0.3 
20% PG/DW 2 4.0 + 0.1 -
40% PG/Dl~ 2 4.1 + 0.3 -
60% PG/DW 2 4.3 + 0.4 
100% PG 6 3. 9 + 0.1 
Azone 3 
l 









All sol ubi li ty and pH values are expressed as mean 









Determination using a Corning Model 125 pH meter with glass 
electrode Ag/AgCl internal reference electrode. 
4 0 '0 
The solubilities were determined at 22 + 0.5. 
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Figure 6. Plot of solubility (S), partition 
coefficient (P) and (P x S) vs percent 
propylene glycol. -
in Azone. The decrease in the solubility of 
isoproterenol HCl with increasing percentages of 
propylene glycol was as predicted by the following 
relationship: 
solubility = -2.88 % propylene glycol + 394.39 
41 
( Eq. 12) 
Skin/Vehicle Partitioning Studies 
The skin/vehicle partition coefficient values of 
isoproterenol HCl are shown in Table V, Figure 6. The 
various vehicles studied were distilled water, propylene 
glycol and 10%, 20%, 40% and 60% v/v propylene glycol in 
water. 
The partition coefficient was found to increase as 
percentage of propylene glycol in the vehicle was 
increased indicating the increasing tendency of drug 
'molecules to partition into the skin from systems rich in 
propylene glycol. 
Selection of Optimal Vehicle 
Equation 1 predicts that the penetration rate across 
the stratum corneum is directly proportional to the 
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TABLE V 
Solubility and Skin/Vehicle Partition Coefficent of 
Isoproterenol HCl in Propylene Glycol/Water Mixtures 
l 2,3 2,3 
Vehicle Solubility Partition s X p 
( s) ' Coefficient 
mg/ml ( p) 
-----------------------------------------------------------
Distilled Water 389.0 0.546 
+ 8.5 + 0.083 
10% PG/DW 357.8 0.465 
+ 5.6 + 0.067 
20% PG/DW 335.1 l. 24 7 
+ 10.3 + O.J67 
40% PG/DW 288.3 l. 438 
+ 2.2 + l. 314 
60% PG/DW 243.3 l. 527 
+ 2.0 + 0.353 
Propylene Glycol 91. 6 5.066 
+ 3 . 4 + l. 341 
l 








The tabulated values are expressed as mean + standard 
error of mean. 
3 0 
Determined at 22 ± 0.5 . 
/ ----~-
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product of the partition coefficient and drug 
concentration present in the donor phase if skin 
thickness (h) and diffusion coefficient of the drug in 
the skin are kept constant. As skin/vehicle partition 
coefficient and solubility are dependent on the 
composition of the vehicle, these parameters could be 
manipulated to attain a desired penetration rate by 
judicious selection of an appropriate vehicle. 
Figure 6 represents the relationship of solubility, 
S and partition coefficient, P and their product, P.S, 
as a function of percent propylene glycol in the vehicle. 
It is seen from this plot that as the percent propylene 
glycol increased in the vehicle, the solubility of 
isoproterenol HCl decreased. On the other hand, there 
was an increase in the partitioning of the drug into the 
skin. The product P.S dropped initially and then 
increased dramatically as the propylene glycol 
concentration in water reached 20% (v/v). Further 
increases in propylene glycol concentration did not show 
significant improvement in P.S values, although the 
maximum P.S value was recorded for 100% (v/v) propylene 
glycol. Therefore, one could predict that 100% (v/v) 
propylene glycol in the water would provide maximum flux 
of isoproterenol HCl across the human skin. However, 
previous studies have established that percentages higher 
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than 40% (v/v) of propylene glycol in the vehicle cause 
dehydration of skin and produce irritational effects. In 
view of these considerations 20% (v/v) propylene glycol 
in water would appear to be the optimal vehicle for 
development of a transderrnal delivery system for 
isoproterenol HCl. 
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EXPERIMENTAL: IN VITRO STUDIES 
This phase of the current investigation included the 
study of the effect of vehicle composition and 
penetration enhancer, Azone, on percutaneous penetration 
of isoproterenol HCl. Further, studies were also 
conducted to understand the relative contributions of 
various species of isoproterenol HCl to the observed flux 
at any given pH. The buffered formulations containing 
specific concentrations of the drug at specific pH values 
were applied to human cadaver skin and the flux was 
calculated from the collected penetration data. The 
permeability co~fficients of various species of 
isoproterenol HCl were then calculated by the procedure 
discussed earlier in the section on theory, and then 
compared to determine the relative permeability of human 
cadaver skin to these species. The same buffered 
formulations were also examined through Azone-pretreated 
skin at specific pH in order to determine if the effect 
of Azone on the skin differentiated between cationic, 
anionic and neutral forms of isoproterenol HCl. 
Preparation of skin: All of the penetration 
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experiments reported here utilized human abdominal skin 
obtained at autopsy. Immediately following excision, the 
skin was placed in a plastic bag and stored in a freezer 
for periods up to (but not exceeding) three months. This 
method of storage has been reported not to damage the 
skin (108,109). Before the experiment, the skin was 
allowed to thaw gradually to room temperature and the 
skin was placed on a smooth dissection board with the 
epidermal surface flat and in contact with the board. 
Subcutaneous fat was completely removed using a scalpel 
and 6-10 pieces of suitable sizes were cut from each 
specimen representing skin of a single donor. 
Experimental Design for Skin Diffusion Studies: 
Each piece of skin was mounted in a special glass 
diffusion cell as illustrated in Figure 7. The skin cell 
consisted of a lower chamber with a sampling port. A 
Teflon-coated magnetic bar was placed at the bottom of 
the cell to provide efficient mixing. The lower chamber 
was enclosed by a water jacket which allowed circulation 
of water at the selected temperature. The skin was 
placed in position on an 0-ring between two ball joints 
of the top and bottom chambers, using a pitch type, 
ground-joint clamp. The diffusion area was 2.01 cm2. The 





Diagrammatic representation of the diffusion 
cell used in penetration studies. Reproduced 
from BenKorah (65). 
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fitting rubber stopper to prevent moisture loss. Normal 
saline was pipetted into the skin cell bathing the dermal 
side. The sampling port was covered by a plastic film20 
and any air bubbles on the dermal side were carefully 
removed by slightly tilting the cell back and forth. 
Each cell was mounted on a magnetic motor. The 
temperature of the fluid in the receptor chamber was 
maintained at 37° + 0.5° by circulating water from a 
constant temperature water circulator21 through the 
jacket of each cell in order to stimulate in vivo 
temperature conditions. After mounting, each piece of 
skin was allowed to stand for 12 h before beginning the 
experiment in order to equilibrate with respect to the 
temperature and relative humidity of the environment. 
One-and-a-half mL of freshly prepared solution of 
isoproterenol HCl in appropriate vehicle was pipetted 
onto the epidermal side of the skin, the rubber stopper 
replaced and the entire skin cell assembly wrapped with 
aluminum foil to protect it from light. 
All experiments were carried out for periods of 
either 12 or 24 h. At selected time intervals (1, 2, 4, 
6, 8, 10, 12 and 24 h) the receptor solution from the 
20. NuggetR, All-Purpose Film, Nugget Distributor, 
Stockton CA. 
21. Haake, Model-FE, VWR Scientific Inc., San 
Francisco CA. 
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bottom chamber was completely removed through the 
sampling port using a disposable syringe with its needle 
attached to a thin flexible plastic tubing. This allowed 
for a quick and complete removal of the receptor solution 
and refilling with fresh normal saline solution. The 
receptor-fluid samples withdrawn were immediately assayed 
for isoproterenol HCl content spectrophotometrically. 
Random samples were also assayed by high pressure liquid 
chromatography and the calculated amount penetrated by 
both methods were compared to check on any unexpected 
decomposition of the drug during penetration studies. 
Effect of Propylene Glycol: One-and-a-half mL of freshly 
prepared suspensions of isoproterenol HCl in 0%, 20%, 60% 
and 100% (v/v) propylene glycol in water were applied to 
the skin in order to determine the effect of propylene 
glycol on percutaneous penetration of isoproterenol HCl. 
The thermodynamic activity of the drug in the respective 
' 
solvent systems was maintained constant by incorporating 
10% excess drug over its solubility. 
Effect of Azone: The effect of the penetration enhancer, 
Azone, on the penetration of isoproterenol HCl through 
human cadaver skin was studied by incorporating selected 
concentrations of Azone in the formulations and by 
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pretreating the skin with Azone. 
The effect of Azone concentration on percutaneous 
penetration of isoproterenol HCl was studied from 
suspensions of Azone in 20% (v/v) propylene glycol in 
water and from gels made with 4% (w/w) hydroxypropyl 
cellulose22 in 20% (v/v) propylene glycol in water. 
The suspensions of 1%, 5%, and 10% (v/v) of Azone in 20% 
(v/v) propylene glycol in water were made by agitating a 
precalculated amount of Azone in 20% (v/v) propylene 
glycol/water mixture·and then adding an excess drug to 
it. The amount of drug in excess of solubility ensured 
constant concentration gradient during the penetration 
experiment. The suspensions containing 1%, 5% and 10% 
(v/v) Azone in 20% (v/v) propylene glycol/water mixture 
were gelled with 4% (w/w) hydroxypropyl cellulose and the 
calculated amount of drug was added to ensure constant 
drug concentration in solution during the experiment. 
The penetration study was conducted by applying 1.5 mL of 
these gels to the epidermal surface of the skin. 
In the pretreatment studies, the human cadaver skin 
piece mounted on the diffusion cell was pretreated with 
0.1 mL of neat Azone for periods of 3, 30, 60 and 720 
22. KlucelR, Grade HF, Lot# 3027, Hercules Inc., 
Wilmington DE. 
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minutes. The epidermal side of the skin was rinsed first 
with 100% ethanol and then with distilled water. It was 
then wiped clean with a micro-wipe23. Penetration 
studies were conducted after applying 1.5 mL of freshly 
prepared suspensions of isoproterenol HCl in 20% (v/v) 
propylene glycol-water maintaining the thermodynamic 
activity constant as before. 
Effect of the pH of the Vehicle on Human Cadaver Skin: 
Twelve diffusion cells were prepared from two separate 
pieces of skin. These cells were divided into three 
groups of 4 cells each. The mean flux from suspensions 
of isoproterenol HCl in distilled water was determined 
for each group for the 12-h study. Then, the donor 
chamber was washed five times with 1 mL distilled water 
each time. The receptor chamber was emptied, rinsed and 
refilled with fresh normal saline, and the donor chambers 
were refilled with appropriate solution. Group 1 was 
treated with distilled water (control), group 2 was 
treated with buffered solution of pH 2, and group 3 was 
treated with buffered solution of pH 10 for 12 h. Then, 
again the donor chambers were washed with distilled water 
(5 x 1 mL). The receptor chamber was emptied and filled 
with fresh normal saline, the donor chamber was covered 
23. Scott Paper Co., Philadelphia PA. 
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with parafilm and the cells were allowed to equilibrate 
for 12 h. The percutaneous penetration study was 
conducted again from suspensions of isoproterenol HCl in 
distilled water for 12 h. The mean flux values 
calculated for each group were compared with flux values 
for the same skin sample prior to exposure to respective 
pH buffer. The data were analyzed statistically by 
ANOVA. This experimental design was dictated by size of 
the available skin samples from human abdominal region 
and requirement of 10-12 skin pieces from each available 
skin sample. 
Effect of pH on Percutaneous Penetration of Isoproterenol 
HCl: Considerable biological variation exists among 
different skin specimens with regard to percutaneous 
penetration (110). The effect of this variable was 
minimized by utilizing skin specimens from the same 
regional site for each experiment. Five sets of 
penetration experiments were carried out in order to have 
statistically meaningful results. In each set, 10 
diffusion cells were prepared using abdominal skin 
samples from the same donor - two for each pH. This 
limitation was dictated by the size of the skin samples 
available from the same site. 
The percutaneous penetration study was conducted 
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using buffered solutions of pH values ranging froM 1.5 to 
9.5 containing known amounts of isoproterenol HCl. The 
mean flux values were calculated after 12-h study. Then 
the donor chamber was washed with distilled water (5 x 1 
mL) and the receptor chamber was rinsed with normal 
saline. After refilling the receptor chamber with fresh 
normal saline, the cells were equilibrated for 12 h. The 
epidermal side was exposed to pure Azone for an hour, 
washed with ethanol (5 x 1 mL) and then distilled water 
(5 x. l mL) to remove excess Azone. The donor side was 
then refilled with the same buffered formulations (but 
freshly prepared) and the penetration study was repeated. 
Permeability coefficients for normal and Azone-pretreated 
skin samples were calculated from experimental flux and 
concentration-values using the method of least squares. 
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RESULTS AND DISCUSSION: IN VITRO STUDIES 
Effect of Propylene Glycol 
All of the penetration data from suspensions of 
isoproterenol HCl (10% in excess) in various propylene 
glycol-water mixtures was analyzed by plotting Q (amount 
penetrated per unit area) against time. A regression 
analyses of the steady-state region of the penetration 
curves (Figure 8) were carried out using a computer24 and 
the data are presented in Table VI. 
Figure 9 shows that as the percentage of propylene 
glycol in the vehicle increased, the flux increased 
initially and then remained essentially constant for 
vehicles containing 20 to 100% (v/v) propylene glycol. 
It is instructive to note that this curve parallels the 
P.S plot shown in Figure 6. It would appear that 
increased partitioning of isoproterenol HCl with 
increasing propylene glycol concentrations and the 
previously reported (25,26) decrease in the diffusional 
resistance of the skin by propylene glycol did not 
adequately compensate for decreased thermodynamic flux. 
24. TeleVideo TPC II/D, Sunnyvale CA. 
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TABLE VI 
Effect of Propylene Glycol on In Vitro Percutaneous 
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The important role of propylene glycol as a 
solubilizer for sparingly soluble non-ionizable drugs in 
dermatological vehicles has been documented by several 
early investigators (17-20). Although increased 
solubility with increasing propylene glycol content in 
the system was accompanied by decreasing the skin/vehicle 
partition coefficient, it had been possible to attain 
desired flux rates for sparingly soluble non-ionizable 
drugs by carefully balancing the two parameters. Recent 
work of Polano and Ponec (111) and Portnoy (112) lends 
additional support to the early work. In this context, 
present data on percutaneous penetration of an ionizable, 
highly water-soluble drug, isoproterenol HCl are 
interesting since drug solubility decreases while 
partitioning into the skin increases with increasing 
propylene glycol concentrations. Regardless, these data 
lend credibility to Fickian diffusion of drugs through 
human skin, stressing the importance of a balance between 
solubility and skin/vehicle partitioning of the drug. 
More importantly, these results suggest the selection of 
20% (v/v) propylene glycol-water as the preferred vehicle 
for topical formulation of isoproterenol HCl as predicted 
earlier on the basis of solubility-partition coefficient 
considerations. 
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Effect of Azone 
Comparison of flux values obtained from suspensions 
of 1, 5 and 10% (v/v} Azone and excess drug in 20% (v/v} 
propylene glycol-water (Table VII, Figure 10} revealed no 
statistically significant differences although l% (v/v} 
Azone appeared to show the maximum effect. On the other 
hand, when the percutaneous study was conducted after 
gelling the suspension formulations listed in Table VII 
with 4% (w/w} hydroxypropyl cellulose, rather interesting 
effects were observed. In the absence of Azone, gelling 
the suspension decreased the flux as revealed by 
comparison of fluxes for control-1 and control-2 (Table 
VIII, Figure 11}. Incorporation of Azone in the gel 
formulation more than compensated for increased 
diffusional resistance of gel resulting in overall 
increase in flux. As previously observed with suspension 
formulation, 1% (v/v} Azone was most effective. 
In order to examine whether the observed enhancement 
of drug penetration by Azone was due to lowered skin 
resistance to drug diffusion, another study was 
conducted. In this study the skin was pretreated with 
Azone for periods of 3, 30, 60, and 720 minutes, prior to 
application of a suspension of isoproterenol HCl in 20% 
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0 10.68 0.9931 
+ l. 76 
3 
1 12.00 0.9962 p > 0.2 
+ l. 47 
3 
5 8.12 0.9969 p > 0.2 
+ l. 94 
3 
10 9.07 0.9906 p > 0.2 





The tabulated flux values are reported ± 95% confidence 
limits. 
Control was a suspension of isoproterenol HCl in 20/80 
PG/water without Azone. 
Test formulations were suspensions of Azone in 20/80 
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Con trol-l 42.93 0.9913 
+ 6.56 -
3 
Control-2 13 0 64 0.9932 
+ l. 84 
4 
1 104.16 0.9991 p < 0.01 p < 0.01 
+ 4.38 
4 
5 95.11 0.9992 p < 0.025 p < 0.025 
+ 4.44 
4 
10 86.69 0.9930 p < 0.05 p < 0.05 
+ 10.29 
The tabu1ated flux values are reported ± 95% confidence 
limits. 
Suspension of isoproterenol HCl in 20/80 PG/water 
without Azone. 
Suspension isoproterenol HCl in 20/80 PG/water gelled 
with 4% (w/w) hydroxypropyl cellulose. 




Effect of Azone on in vitro percutaneous 
penetration of isoproterenol HCl from gels. 
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flux values for each treatment period were compared with 
that of untreated control skin from same donor. The 
results, presented in Figure 12 and Table IX, revealed 
that the fluxes of 30- and 60-minute pretreated samples 
were significantly different (P < 0.025) from the 
untreated control. Single 30-60 minute exposure to Azone 
provided maximum rate of percutaneous penetration which 
is in agreement with the work of BenKorah et al. (65) on 
benzocaine. Therefore, 60-minute pretreatment period was 
selected for subsequent studies. 
In order to test these findings further, yet another 
experiment was conducted using skin from abdominal region 
of the same donor. A suspension of excess isoproterenol 
HCl in 20% (v/v) propylene glycol-water was applied to 
60-minute Azone-pretreated skin and untreated skin. A 
similar formulation with 1% (v/v) Azone was applied to 
another untrBated skin in the same study. An analysis of 
the mean steady-state flux values presented in Table X 
(Figure 13) showed that pretreatment of skin was more 
effective in enhancing penetration of isoproterenol HCl 
through hwnan cadaver skin than the incorporation of 
Azone in the formulation, strongly suggesting direct 
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12.22 0.9913 p > 0.35 
2.25 
23.16 0.9984 p < 0.025 
3.94 
23.85 0.9999 p < 0.025 
0.89 
19.13 0.9987 p < 0.01 
1.12 
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Comparison of the Effect of 1% (v/v) Azone in the Vehicle 
and Azone Pretreatment (60 minutes) on In Vitro 
Percutaneous Penetration of Isoproterenol HCl 
Flux 



























0.9999 p < 0.025 
0.9943 p < 0.05 
The tabulated flux values are reported ± 95% confidence 
limits. 
Skin exposed to suspension of isoprot·:,renol HCl in 
20/80 PG/Water without Azone. 
Skin pretreated with pure Azone for 60 minutes and exposed 
to suspension of isoproterenol HCl in 20/80 PG/water. 
Skin exposed to suspension of isoproterenol HCl in 20/80 
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Figure 13. Effect of 1% Azone in the vehicle and Azone 
pretreatment (60 minutes) on in vitro · 







Effect of pH of the Vehicle on Human Cadaver Skin 
The effect of hydrogen ion concentration per ~ and 
the effect of Azone on percutaneous penetration of 
isoproterenol HCl were examined over a pH range of 1.5 to 
9.5. The experimental design dictated by the size of the 
available skin specimen from the same region of the same 
donor required reusing the skin. In order to relate 
changes in flux at various pH levels to effects of Azone, 
it was necessary to account for any changes in the 
permeability of skin caused by deterioration with time 
and/or exposure to extreme pH conditions. 
A percutaneous penetration study was done by 
treating the skin with buffered solutions of pH 2 and pH 
10. The control in the study was treated with distilled 
water. Table XI and figure 14 show the in vitro effects 
of pH on the skin. Comparing the flux values of 
isoproterenol HCl through the skin before and after 
treatment of the skin sample with a solution of 
respective pH, it is seen that there was no significant 
difference (P > 0.05) in the flux values as checked by 
testing the parallelism of the steady-state regions of 
the two curves, although, there was significant 
difference (P < 0.05) in the amount penetrated per time 
interval as tested by paired T-Test. The presence of a 
... L 
TABLE XI 
Effect of pH of the Vehicle on Human Cadaver Skin 
2 
Q (meg/em ) Time, 
h ------------------------------------------------------------------
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Figure 14. Effect of pH of the vehicle on human cadaver 
skin. 
72 
slight curvature in the pre-steady state region of the 
penetration curves for all treated samples in Figure 14 
suggested that this difference was possibly due to a 
delay in the attainment of steady-state resulting from 
partial dehydration of the skin brought about by osmotic 
effects of the solutions on both sides of the skin. Our 
interpretation is consistent with the observations of 
early investigators (113-115) that hydration of the skin 
plays a significant role in percutaneous penetration of 
drugs. From this study, it was concluded that exposure 
of the epidermal side of the skin to isoproterenol HCl 
suspension in water, pH 2 and pH 10 buffer solutions and 
simultaneous exposure to the dermal side of the same skin 
specimen to normal saline for a period of 12 h did not 
significantly change the flux. 
Effect of pH on Percutaneous Penetration of Isoproterenol 
HCl 
Having established the effect of pH and duration of 
study on the skin, the same experimental design was used 
to study the effect of Azone on skin permeability towards 
various ionic and nonionic forms of isoproterenol HCl 
under varying conditions of pH. Each experimental set 
(sets 1-5) included two penetration studies (identified 
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as a and b ) on the same sample of skin at each pH before 
and after treatment with Azone. Figures 15, 17, 19, 21, 
and 23 and Tables XII, XIV, XVI, XVIII, and XX represent 
flux data before treatment with Azone while Figures 16, 
18, 20, 22, and 24 and tables XIII, XV, XVII, XIX, and 
XXI represent the flux data after Azone treatment. The 
experimental design of each set, enabled comparison of 
fluxes at four pH values to that of the control. Since 
initial drug concentrations were not identical but only 
approximately similar within each study, comparison of 
the fluxes was suggestive but not conclusive in 
indicating the direction of change in flux with 
increasing pH. These data suggested maximum flux between 
pH 8-9.5 in agreement with predictions based upon pH-pKa 
relationship. The concentration of neutral (uncharged 
and zwitterionic) species would be maximum around pH of 
9. The neutral species were found to have higher 
permeability coefficients compared to anionic and 
cationic species. The neutral, cationic and anionic 
species have permeability coefficients of 0.2098 x lo-3 
cm/h, 0.1570 x lo-4 cm/h and -0.8665 x lo-3 cm/h 
respectively. as calculated from equation 8 and listed in 
the Table XXII. 
J = ( Kp . C )Ca + ( Kp . C )an + ( Kp . C )n 
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The tabulated flux values are reported : 95% confidence 
limits. 
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Figure 15. Effect of pH on in vitro percutaneous 
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The tabulated flux values are reported ~ 95% confidence 
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Figure 16. Effect of pH on in vitro percutaneous 
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The tabulated flux values are reported ~ 95% confidence 
limits. 
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Figure 17. . Effect of pH on in vitro percutaneous 
penetration of isoproterenol HCl. 






Effect of pH on In Vitro Percutaneous Penetration of 
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The tabulated flux values are reported ± 95% confidence 
limits. 
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The tabulated flux values are reported ± 95% confidence 
limits. 
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The tabulated flux values are reported ! 95% confidence 
limits. 
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The tabulated flux values are reported ~ 95% confidence 
limits. 
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Effect of pH on In Vitro Percutaneous Penetration of 
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The tabulated flux values are reported ± 95% confidence 
limits. 
Suspension of isoproterenol HCl in distilled water, pH 3.9. 
Figure 22. 
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The tabulated flux values are reported ± 95% confidence 
limits. 
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pH 2.0 92.1 34.43 0.9998 
+ l. 39 
pH 6.9 90.3 12.39 0.9884 
+ l. 90 -
pH 7.9 103.2 19.06 0.9994 
+ l. 23 -
pH 8.5 99 0 9 23.70 0.9996 
+ 1.12 
The tabulated flux values are reported ± 95% confidence 
limits. 
Suspension of isoproterenol HCl in distilled water, pH 3.9. 
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Untreated Skin 0.000210 0.000016 -0.000866 
+ 0.000154 + 0.000068 + 0.000877 
1 
Treated Skin 0.000840 0.000170 0.008091 
+ 0.000724 + 0.000193 + 0.015448 
1 
The skin was pretreated with pure Azone for 60 minutes. 
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When the skin was pretreated with Azone, similar 
results were seen. There was an increase in the rate of 
percutaneous penetration with increasing pH (Tables 
XIII,V,VII,IX,XXI; Figures 16,18,20,22,24). Table XXII 
also lists the permeability coefficients of different 
species of isoproterenol HCl through Azone-pretreated 
human cadaver skin. These are 0.8395 x lo-3 cm/h for the 
neutral species, 0.1701 x lo-3 cm/h for the cationic 
species and 0.8091 x lo-2 cm/h for the anionic species, 
respectively. From a comparison of these values with 
those obtained from the untreated skin, it can be seen 
that Azone treatment enhanced the percutaneous 
penetration of all species of isoproterenol HCl, although 
the anionic species was favored the most. Previous 
investigation BenKorah et al. (65) had established that 
Azone enhances percutaneous penetration of both 
hydrophilic and hydrophobic molecules by lowering che 
skin's resistance to diffusion of penetrant molecules. 
The results of the present investigation not only 
confirms BenKorah's work but further extends our 
understanding of the mechanism of penetration enhancement 
by Azone by revealing that an anionic character is a more 
desirable attribute of hydrophilic molecules. Although 
there are no other literature citations substantiating 
our findings, Hadgraft et al.(67) recently reported --
similar observations while studying penetration of 
salicylates through a filter paper impregnated with 
isopropyl myristate. 
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Paired t-Tests on the experimental flux values and 
the flux values calculated using the permeability 
coefficients from Table XXII for both, untreated and 
Azone-pretreated human cadaver skin showed no significant 
difference (P > 1.0) (Table XXIII). This was further 
confirmed by an excellent correlation between the 
calculated flux and experimental flux [ r (untreated 
skin) = .1.000, r (Azone-pretreated) = 0.999 ] as seen in 
the regression plots (Figures 25-26). Furthermore, these 
results validated the hypothesis (equation 8) and 
assumptions that were made therein. 
The flux values for untreated and Azone-pretreated 
skin were calculated from equation 8 using permeability 
coefficients from Table XXII and percent concentrations 
of neutral, cationic and anionic forms of isoproterenol 
HCl obtained from equation 3,4,5 and 6. These flux 
values were then plotted as a function of pH and the plot 
was superimposed on the plot of % concentration of 
various species of isoproterenol HCl against pH (Figure 
27). For attaining maximum flux through untreated and 
Azone-pretreated skin, it was now possible to see that 
optimal pH would be 9 and 12 respectively, far beyond the 
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TABLE XXIII 
Experimental and Calculated Flux Values for In Vitro 























Flux, mg/cm /h 
l 
Untreated Skin Treated Skin 
Experimental Calculated Experimental Calculated 
0.0196 0.0204 0.0258 0.0444 
0.0247 0.0343 0.0507 0.0735 
0.0205 0.0377 0.0415 0.1063 
0.0265 0.0244 0.0348 0.0712 
0.0125 0.0208 0.0691 0.0432 
0.0535 0.0282 0.1125 0.0860 
0.0214 0.0278 0.0991 0.0874 
0.0527 0.0373 0.1987 0.1542 
0.0156 0.0176 0.0103 0.0146 
0.0223 0.0195 0.0312 0.0242 
0.0233 0.0220 0.0371 0.0321 
0.0257 0.0237 0.0581 0.0535 
0.0259 0.0178 0.0159 0.0156 
0.0191 0.0201 0.0237 0.0247 
0.0234 0.0245 0.0809 0.0465 
0.0238 0.0258 0.0955 0.1033 
0.0116 0.0178 0.0344 0.0141 
0.0106 0.0181 0.0124 0.0145 
0.0232 0.0201 0.0191 0.0237 
0.0260 0.0239 0.0237 0.0418 
Paired t-Test p 
Untreated Skin: J(exp) vs J(ca1c) > l. 0 
Treated Skin: J(exp) vs J(ca1c) > 1.0 
l 
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Figure 25. Relationship between calculated and 
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Figure 27. Projected plot of the effect of pH on the 
total flux through untreated and Azone-
pretreated skin and effect of pH on the 




clinically acceptable range. Nevertheless, this approach 
can be used for confirming the optimal pH environment for 
percutaneous penetration and for studying vehicle effects 
for any ionizable drug molecule. 
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SUMMARY AND CONCLUSIONS 
Much of the theoretical background for percutaneous 
penetration has been developed through studies of non-
ionizing molecules. There are very few literature 
citations in the area of permeation of ionizable 
compounds through the skin. Even the penetration 
enhancing strategies have been tested mainly using non-
ionizing compounds. The situation is especially acute 
with respect to availability of information on the effect 
of solubility, skin/vehicle partitioning, vehicle 
composition, pH of the vehicle and penetration enhancers 
on the permeation of electrolytes. 
Depending on the pKa of the compound and pH of the 
vehicle, a permeating electrolyte exists as an 
equilibrium mixture of ionized and unionized species in 
the immediate vicinity of the skin. Although passive 
diffusion across the skin favors the unionized species of 
the electrolyte, permeation of ionized forms of the 
molecules is also possible and cannot be assumed to be 
negligible, especially when their concentration is high. 
The permeability coefficients of the unionized molecules 
have been found to be much greater than those of ionized 
103 
species. 
In the present work, three important physicochemical 
properties (stability, solubility and partition 
coefficient) of an ionizable drug, isoproterenol HCl, 
have been examined. The stability studies were conducted 
in distilled water, normal saline, propylene glycol and a 
series of propylene glycol-water mixtures (10, 20, 40, 60 
% v/v) at 22° + o.so and in normal saline in presence and 
absence of EDTA at 370 + O.so in order to define optimal 
experimental conditions for subsequent studies. The 
solubility determination was carried out in distilled 
water, propylene glycol, various propylene glycol water 
mixtures (10, 20, 40, 60% v/v) and Azone at 220 + 0.5°. 
The partition coefficient determinations were conducted 
in distilled water, propylene glycol and various 
propylene glycol-water mixtures (10, 20, 40, 60% v/v) at 
220 + O.so. The solubility and partition coefficient 
results were later utilized to understand and explain the 
skin penetration of isoproterenol HCl across human 
cadaver skin. 
The effect of propylene glycol concentrations in the 
vehicle on percutaneous penetration of isoproterenol HCl 
has been investigated at 0, 20, 60, 100% (v/v) in 
distilled water. The effect of Azone on skin penetration 
of isoproterenol HCl has been studied by incorporating 1, 
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5, 10% (v/v) Azone in 20/80 propylene glycol-water 
vehicle and also by treating the skin with neat Azone for 
3-, 30-, 60- and 720-minute periods prior to application 
of the drug formulation. Finally, the skin penetration 
of isoproterenol HCl was investigated under varying 
conditions of pH through untreated and Azone-pretreated 
skin. The flux and permeability coefficient values 
calculated from these studies, were utilized to test the 
proposed model for penetration of the ionizable drug, 
isoproterenol HCl, through human cadaver skin under 
varying conditions of pH in order to understand the 
penetration enhancing effects of Azone upon the various 
ionic forms of isoproterenol HCl. 
Isoproterenol HCl is very stable (less than l% 
decomposition) in water, normal saline, propylene glycol 
and 10, 20, 40, 60% (v/v) propylene glycol-water mixtures 
for 24 hat 22° + 0.5° in the pH range 1 to 7. The rate 
of decomposition of isoproterenol HCl in aqueous 
solutions increased as the pH was increased beyond pH 
8.0. The rate of decomposition of isoproterenol HCl in 
normal saline increased significantly with increase-in 
temperature to 37° ~ O.so. The solubility of 
isoproterenol HCl was found to decrease and skin/vehicle 
partition coefficient of the drug increased with 
increasing proportions of propylene glycol in the 
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vehicle, while the product of solubility and partition 
coefficient appeared to plateau at 20% (v/v) propylene 
glycol. On the basis of these results and reports of low 
irritability, 20% (v/v) propylene-glycol in water was 
predicted as the optimal vehicle for transdermal delivery 
of isoproterenol HCL. 
The results of the penetration study conducted to 
examine the effect of propylene glycol on percutaneous 
penetration of isoproterenol HCl appeared to confirm the 
choice of 20% (v/v) propylene glycol-water system as the 
optimal solvent for isoproterenol HCl. The increasing 
permeability coefficients with increases in proportion of 
propylene glycol in the formulation appear to confirm 
that propylene glycol facilitates penetration of drug 
molecules across human skin by lowering the diffusional 
resistance. 
Azone pretreatment was more effective in enhancing 
percutaneous penetration than incorporating Azone in the 
vehicle, confirming observations of BenKorah et al. (65). 
Optimal penetration enhancing effects of Azone were seen, 
when incorporated at a level of 1% (v/v) in the vehicle 
and also when the skin was pretreated vdth pure Azone for 
60 minutes prior to application of drug formulation. The 
flux appeared to reach a maximum around pH 9 in agreement 
with the predicted optimal pH environment (pH 8.5 to 9.5) 
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for neutral forms of isoproterenol HCl on the basis of 
pH-pKa relationship. Permeability coefficients of 
various species of isoproterenol HCl for penetration 
through untreated cadaver skin further confirmed this 
fact. The permeability coefficients were found to be 
0.2098 x lo-3 cm/h, 0.1570 x lo-4 cm/h and -0.8665 x 
lo-3 cm/h for the neutral, cationic and anionic species, 
respectively. The permeability coefficients of the 
various species of isoproterenol HCl for skin pretreated 
with Azone were 0.8395 x lo-3 cm/h, 0.1701 x lo-3 cm/h, 
0.8091 x lo-2 em /h for the neutral, cationic and anionic 
species, respectively. Comparing these with the 
permeability coefficients through the untreated skin 
revealed that Azone, in general, enhanced the penetration 
of all forms of isoproterenol HCl, although the effect 
was more pronounced for the anionic species. The latter 
effect could be explained by formation of an ion-pair 
between isoproterenol anion and Azone, analogous to the 
salicylate anion-Azone ion pair proposed by Hadgraft 
( 6 7 ) • 
The paired t-test and regression analyses on the 
calculated and experimental flux values from untreated 
and Azone-pretreated human cadaver skin confirmed the 
validity of the proposed model (equation 8) and its 
underlying assumptions. 
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J = ( Kp . c )Ca + ( Kp . c )an + ( Kp . c )n 
( Eq. 8 ) 
From the results of this investigation, it was 
evident that although isoproterenol HCl has a poor 
penetration rate across the skin, it could be 
administered transdermally in therapeutically significant 
amounts by either incorporating 1% (v/v) Azone in the 
20/80 propylene glycol-water system or pretreating the 
skin with Azone before application of the same drug 
formulation. Isoproterenol HCl is administered at 5 
meg/min by intravenous infusion. If this rate of drug 
delivery is also recognized as clinically acceptable by 
the transdermal route, then a suspension of isoproterenol 
HCl in 20/80 propylene glycol-water system would have to 
be applied over an aree of 23 cm2. Incorporation of 1% 
(v/v) Azone in the formulation would require an area of 
application of 19 cm2 to achieve the same rate of drug 
delivery. Pretreatment of the skin prior to application 
of the drug formulation would further reduce the area of 
application to 12.5 cm2. Since the pretreatment of skin 
is more effective in enhancing the percutaneous 
penetration of isoproterenol HCl, the conventional 
transdermal delivery system could be modified by 
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incorporating Azone in the adhesive layer of this system, 
thereby bringing Azone in contact with the skin prior to 
the drug molecules. Since considerable intra- and inter-
subject variation exists in the skin and isoproterenol 
HCl is prone to degradation, in vivo studies must be 
conducted before any conclusive statements can be made. 
This investigation further stresses the importance 
of basic physicochemical studies and the usefulness of 
rigorous mathematical and graphic analyses of data in 
designing transdermal drug delivery systems. 
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